IP Library Granted Patent US 9,011,928
Granted Patent B2
US 9,011,928 · App. 14/074,201 · Granted Apr 21, 2015

Compositions for achieving a therapeutic effect in an anatomical structure

Inventors: Wouter E. Roorda (Palo Alto, CA); Stephen D. Pacetti (San Jose, CA)
Assignee: Abbott Cardiovascular Systems Inc.
A61K9/14A61K9/1617A61K9/1647A61K9/1658A61K31/727A61K47/26A61K47/36A61K31/573A61K38/1825A61K9/1694A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,011,928
App. No.
14/074,201
Granted
Apr 21, 2015
Kind
B2
Abstract

Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.

Claims (17)

1. A composition to form an embolus within a vascular lumen, the composition comprising a solid particle comprising a hydrophobic solid, a surfactant and a therapeutic substance; wherein the particle forms the embolus within the vascular lumen for a transitory period of less than one week;

wherein the hydrophobic solid is a solid triglyceride, cholesterol, or a combination thereof;

and

wherein the surfactant is selected from the group consisting of sorbitan esters, polyethoxylated sorbitan esters, poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) triblock copolymers, and combinations thereof.

2. The composition of claim 1 , wherein the surfactant comprises a sorbitan ester.

3. The composition of claim 1 , wherein the therapeutic substance is selected from the group consisting of antineoplastic, antiplatelet, anticoagulant, fibrinolytic, antimitotic, thrombin inhibitor, anti-inflammatory, antiproliferative, antioxidant, antiangiogenic, angiogenic, arteriogenic and antiallergic substances, and combinations thereof.

4. The composition of claim 1 , wherein the surfactant comprises a polyethoxylated sorbitan ester.

5. The composition of claim 1 , wherein the surfactant comprises a poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) triblock copolymer.

6. The composition of claim 1 , wherein the hydrophobic solid is cholesterol.

7. The composition of claim 1 , wherein the hydrophobic solid is a solid triglyceride.

8. The composition of claim 1 , wherein the particle further comprises a disintegrant.

9. The composition of claim 8 , wherein the disintegrant is croscarmellose.

10. The composition of claim 8 , wherein the disintegrant is povidone.

11. The composition of claim 8 , wherein the disintegrant is lactose.

12. The composition of claim 8 , wherein the disintegrant is mannose.

13. The composition of claim 1 , wherein the diameter of the particle is reduced within the vascular lumen or the particle disintegrates into fragments with the vascular lumen.

14. The composition of claim 8 , wherein the diameter of the particle is reduced within the vascular lumen or the particle disintegrates into fragments within the vascular lumen.

Continuity (5)
Division 13244294 · Sep 24, 2011
Continuation 12198749 · Aug 26, 2008
Division 11015943 · Dec 17, 2004
Division 09781599 · Feb 12, 2001
Related Publication 20140065093A1 · Mar 6, 2014